Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Medicus Pharma Ltd
Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
May 24, 2026
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset
May 23, 2026
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate
May 22, 2026
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
May 22, 2026
Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst
May 20, 2026
Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26
May 20, 2026
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum
March 10, 2026
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
March 9, 2026
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
February 2, 2026
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
January 28, 2026
←
Previous Page
1
2